Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

Journal of Virology

Volumn 77, Issue 2, 2003, Pages 1610-1613

  Labrosse, Béatrice ^a   Labernardière, Jean Louis ^b   Dam, Elisabeth ^b   Trouplin, Virginie ^b   Skrabal, Katharina ^a   Clavel, François ^a   Mammano, Fabrizio ^a  

^a BICHAT HOSPITAL   (France)

^b Viralliance   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); CHEMOKINE RECEPTOR; ENFUVIRTIDE; GLYCOPROTEIN GP 41; RANTES;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG SENSITIVITY; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PLASMA; PRIORITY JOURNAL; VIRUS INHIBITION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CELL LINE; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MEMBRANE FUSION; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; RECEPTORS, CCR5; RECEPTORS, CXCR4; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0037223692     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.77.2.1610-1613.2003     Document Type: Article

References (28)

1. Alkhatib, G., C. Combadiere, C. C. Broder, Y. Feng, P. E. Kennedy, P. M. Murphy, and E. A. Berger. 1996. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 272: 1955-1958.
2. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700.
3. Brelot, A., and M. Alizon. 2001. HIV-1 entry and how to block it. AIDS 15(Suppl. 5):S3-S11.
4. Chan, D. C., and P. S. Kim. 1998. HIV entry and its inhibition. Cell 93:681-684.
5. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P. D. Ponath, L. Wu, C. R. Mackay, G. LaRosa, W. Newman, N. Gerard, C. Gerard, and J. Sodroski. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
6. Chou, T.-C. 1991. The median-effect principle and the combination index for quantitation of synergism and antagonism, p. 61-102. In T.-C. Chou and D. C. Rideout (ed.). Synergism and Antagonism in Chemotherapy. Academic Press, San Diego, Calif.
7. Deng, H., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R. E. Sutton, C. M. Hill, C. B. Davis, S. C. Peiper, T. J. Schall, D. R. Littman, and N. R. Landau. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
8. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, X. Wu, W. A. O'Brien, L. Ratner, J. C. Kappes, G. M. Shaw, and E. Hunter. 2000. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J. Virol. 74:8358-8367.
9. Derdeyn, C. A., J. M. Decker, J. N. Sfakianos, Z. Zhang, W. A. O'Brien, L. Ratner, G. M. Shaw, and E. Hunter. 2001. Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor. J. Virol. 75:8605-8614.
10. Donzella, G. A., D. Schols, S. W. Lin, J. A. Este, K. A. Nagashima, P. J. Maddon, G. P. Allaway, T. P. Sakmar, G. Henson, E. De Clercq, and J. P. Moore. 1998. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat. Med. 4:72-77.
11. Doranz, B. J., J. Rucker, Y. Yi, R. J. Smyth, M. Samson, S. C. Peiper, M. Parmentier, R. G. Collman, and R. W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85:1149-1158.
12. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
13. Harrigan, P. R., J. S. Montaner, S. A. Wegner, W. Verbiest, V. Miller, R. Wood, and B. A. Larder. 2001. World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 15:1671-1677.
14. Heveker, N. 2001. Chemokine receptors as anti-retroviral targets. Curr. Drug Targets 2:21-39.
15. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw, and M. S. Saag. 1998. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med. 4:1302-1307.
16. Kliger, Y., and Y. Shai. 2000. Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation. J. Mol. Biol. 295:163-168.
17. Labrosse, B., A. Brelot, N. Heveker, N. Sol, D. Schols, E. De Clercq, and M. Alizon. 1998. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J. Virol. 72:6381-6388.
18. Myers, G., B. T. Korber, B. T. Foley, K.-T. Jeang, J. W. Mellors, and S. Wain-Hobson. 1997. Human Retroviruses and AIDS 1997: A Compilation and Analysis of Nucleic Acid and Amino Acid Sequences. Theoretical Biological and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N.Mex.
19. Poignard, P., E. O. Saphire, P. W. Parren, and D. R. Burton. 2001. Gp120: Biologic aspects of structural features. Annu. Rev. Immunol. 19:253-274.
20. Rimsky, L. T., D. C. Shugars, and T. J. Matthews. 1998. Determinants of human immunodefieiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72:986-993.
21. Schols, D., S. Struyf, J. Van Damme, J. A. Este, G. Henson, and E. De Clercq. 1997. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J. Exp. Med. 186:1383-1388.
22. Sodroski, J. G. 1999. HIV-1 entry inhibitors in the side pocket. Cell 99:243-246.
23. Stephenson, J. 2002. Researchers explore new anti-HIV agents. JAMA 287: 1635-1637.
24. Trouplin, V., F. Salvatori, F. Cappello, V. Obry, A. Brelot, N. Heveker, M. Alizon, G. Scarlatti, F. Clavel, and F. Mammano. 2001. Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J. Virol. 75:251-259.
25. Wei, X., J. M. Decker, H. Liu, Z. Zhang, R. B. Arani, J. M. Kilby, M. S. Saag, X. Wu, G. M. Shaw, and J. C. Kappes. 2002. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob. Agents Chemother. 46:1896-1905.
26. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal, and T. J. Matthews. 1994. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. USA 91:9770-9774.
27. Wyatt, R., and J. Sodroski. 1998. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280:1884-1888.
28. Zollner, B., H. H. Feucht, M. Schroter, P. Schafer, A. Plettenberg, A. Stoehr, and R. Laufs. 2001. Primary genotypic resistance of HIV-1 to the fusion inhibitor T-20 in long-term infected patients. AIDS 15:935-936.